Immunotherapy combo shows promise in esophageal cancer trial
NCT ID NCT02998268
First seen Apr 20, 2026 · Last updated May 24, 2026 · Updated 6 times
Summary
This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation helps people with advanced esophageal cancer. About 42 adults with cancer that had not spread to other organs took part. The main goal was to see if the combination improved the chance of being cancer-free one year after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
USC Keck School of Medicine, Norris Cancer Center
Los Angeles, California, 90033, United States
-
University of Michigan
Ann Arbor, Michigan, 48109-5848, United States
-
Weill Cornell Medicine
New York, New York, 10068, United States
Conditions
Explore the condition pages connected to this study.